Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron
Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6® cell line for use in the manufacturing of Chiron's prophylactic hepatitis C vaccine, which is currently in phase I clinical trials. Financial details were not disclosed.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.